A French academic breast oncologist shares perspectives on the HER2-positive breast cancer treatment landscape, including neoadjuvant and adjuvant management, treatment de-escalation, use of trastuzumab deruxtecan (T-DXd/Enhertu) in early and metastatic settings, reimbursement challenges in France, second- and third-line sequencing, and areas of unmet need. The KOL also discusses emerging agents including palbociclib (PATINA regimen), inavolisib, giredestrant, zanidatamab, and vaccine immunotherapies.

This interview was conducted on April 09, 2026.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.